Eupraxia Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. The company leverages its proprietary polymer-based micro-sphere technology, Diffusphere™, to optimize drug delivery, providing hyper-localized, controlled therapeutic release directly to target tissues while minimizing systemic exposure. Eupraxia's lead clinical program is EP-104, which is being developed under two distinct pathways: EP-104IAR for the treatment of chronic pain associated with knee osteoarthritis (OA), and EP-104GI for the treatment of eosinophilic esophagitis (EoE).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of EP-104GI, an extended-release formulation of fluticasone propionate utilizing the proprietary Diffusphere technology, administered via local submucosal injection for eosinophilic esophagitis (EoE).
Expected impact: Provides a highly localized, long-acting therapeutic option for EoE with minimal systemic steroid exposure, addressing a multi-billion dollar addressable market.
Expanding the application of the Diffusphere drug delivery platform and EP-104GI into additional gastrointestinal indications beyond eosinophilic esophagitis.
Expected impact: Broadens the addressable market and therapeutic utility of the Diffusphere platform across other inflammatory and fibrotic GI conditions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating with NBCD, a specialized contract research organization, to design and conduct clinical trials for Eupraxia's osteoarthritis candidate (EP-104IAR).
Terms: Terms include service-based fees and operational milestones for trial execution.